{"generic":"Peginterferon Alfa-2b","drugs":["Peg Intron RP","PEG-Intron","Peginterferon Alfa-2b","Sylatron"],"mono":[{"id":"926101-s-0","title":"Generic Names","mono":"Peginterferon Alfa-2b"},{"id":"926101-s-1","title":"Dosing and Indications","sub":[{"id":"926101-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 65 kg or less, 1.5 mcg\/kg\/wk SUBQ with ribavirin 400 mg ORALLY twice daily for 48 weeks in genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor and genotypes 2 or 3<\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 66 to 80 kg, 1.5 mcg\/kg\/wk SUBQ with ribavirin 400 mg ORALLY in the morning and 600 mg ORALLY in the evening for 48 weeks in genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor and genotypes 2 or 3 <\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 81 to 105 kg, 1.5 mcg\/kg\/wk SUBQ with ribavirin 600 mg ORALLY twice daily for 48 weeks in genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor and genotypes 2 or 3<\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> greater than 105 kg, 1.5 mcg\/kg\/wk SUBQ with ribavirin 600 mg ORALLY in the morning and 800 mg ORALLY in the evening for 48 weeks in genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor and genotypes 2 or 3<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 65 kg or less, 1.5 mcg\/kg\/wk SUBQ with ribavirin 400 mg ORALLY twice daily for 48 weeks for genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor, or 24 weeks for genotypes 2 and 3<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 66 to 80 kg, 1.5 mcg\/kg\/wk SUBQ with ribavirin 400 mg ORALLY in the morning and 600 mg ORALLY in the evening for 48 weeks for genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor, or 24 weeks for genotypes 2 and 3<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 81 to 105 kg, 1.5 mcg\/kg\/wk SUBQ with ribavirin 600 mg ORALLY twice daily for 48 weeks for genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor, or 24 weeks for genotypes 2 and 3<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> greater than 105 kg, 1.5 mcg\/kg\/wk SUBQ with ribavirin 600 mg ORALLY in the morning and 800 mg ORALLY in the evening for 48 weeks for genotype 1 with or without an approved Hepatitis C Virus (HCV) NS3\/4A protease inhibitor, or 24 weeks for genotypes 2 and 3<\/li><li><b>Hepatitis C, chronic, Monotherapy in interferon alpha-naive with compensated liver disease:<\/b> monotherapy, 1 mcg\/kg\/wk SUBQ for 1 year<\/li><li><b>Malignant melanoma; Adjunct:<\/b> 6 mcg\/kg\/wk SUBQ for 8 doses, then 3 mcg\/kg\/wk SUBQ for up to 5 years; premedicate with acetaminophen 500 mg to 1000 mg ORALLY 30 minutes prior to first dose and as needed for subsequent doses<\/li><\/ul>"},{"id":"926101-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>(hepatitis C) pediatric patients who reach their 18th birthday while receiving peginterferon alfa-2b and ribavirin should remain on the pediatric dosing regimen<\/li><li>(melanoma) safety and effectiveness of peginterferon alfa-2b for the treatment of melanoma in pediatric patients younger than 18 years of age have not been established<\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 3 years and older (less than 47 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 15 mg\/kg\/day ORALLY in 2 divided doses for 48 weeks for all genotypes <\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 3 years and older (47 to 59 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 400 mg ORALLY twice daily for 48 weeks for all genotypes<\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 3 years and older (60 to 73 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 400 mg ORALLY in the morning and 600 mg ORALLY in the evening for 48 weeks for all genotypes<\/li><li><b>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease:<\/b> 3 years and older (greater than 73 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 600 mg ORALLY twice daily for 48 weeks for all genotypes <\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 2 years and older, 60 mcg\/m(2) SUBQ weekly with ribavirin 15 mg\/kg daily ORALLY for 48 weeks (guideline dosing)<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 3 years and older (less than 47 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 15 mg\/kg\/day ORALLY in 2 divided doses for 48 weeks for genotype 1, or 24 weeks for genotypes 2 and 3 (manufacturer dosing)<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 3 years and older (47 to 59 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 400 mg ORALLY twice daily for 48 weeks for genotype 1, or 24 weeks for genotypes 2 and 3 (manufacturer dosing)<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 3 years and older (60 to 73 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 400 mg ORALLY in the morning and 600 mg ORALLY in the evening for 48 weeks for genotype 1, or 24 weeks for genotypes 2 and 3 (manufacturer dosing)<\/li><li><b>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease:<\/b> 3 years and older (greater than 73 kg), 60 mcg\/m(2)\/wk SUBQ with ribavirin 600 mg ORALLY twice daily for 48 weeks for genotype 1, or 24 weeks for genotypes 2 and 3 (manufacturer dosing)<\/li><\/ul>"},{"id":"926101-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>(hepatitis C, combination therapy) depression, adult:<\/b> initial management (4-8 weeks) of moderate depression, decrease dose to 1mcg\/kg\/wk then to 0.5 mcg\/kg\/wk (if needed), if symptoms improve and are stable for 4 weeks, reduced dose may be continued or reinstitute normal dosing; permanently discontinue therapy with severe depression<\/li><li><b>(hepatitis C, monotherapy) depression, adult:<\/b> initial management (4-8 weeks) of moderate depression, decrease dose to 0.5 mcg\/kg\/week, if symptoms improve and are stable for 4 weeks, reduced dose may be continued or reinstitute normal dosing; permanently discontinue therapy with severe depression<\/li><li><b>(hepatitis C) depression, pediatric:<\/b> initial management (4-8 weeks) of moderate depression, decrease dose to 40 mcg\/m(2)\/week then to 20 mcg\/m(2)\/week (if needed), if symptoms improve and are stable for 4 weeks, reduced dose may be continued or may reinstitute normal dosing; permanently discontinue therapy with severe depression<\/li><li><b>(hepatitis C) cardiac disease, adult:<\/b> reduce dose by 50% if Hgb less than 10 g\/dL; if a greater than 2 g\/dL decrease in Hgb is observed in any 4-week period in adults with stable cardiac disease reduce dose by 50%; permanently discontinue therapy if Hgb less than 12 g\/dL after a ribavirin dose reduction<\/li><li><b>(hepatitis C, combination therapy) hematologic, adult:<\/b> reduce dose to 1 mcg\/kg\/wk then to 0.5 mcg\/kg\/wk (if needed), if WBC is less than 1.5 x 10(9)\/L, neutrophils less than 0.75 x 10(9)\/L, or platelets less than 50 x 10(9)\/L; permanently discontinue if WBC less than 1 x 10(9)\/L, neutrophils less than 0.5 x 10(9)\/L, or platelets less than 25 x 10(9)\/L, Hgb is less than 8.5 g\/dL<\/li><li><b>(hepatitis C, monotherapy) hematologic, adult:<\/b> reduce dose to 0.5 mcg\/kg\/wk if WBC is less than 1.5 x 10(9)\/L, neutrophils less than 0.75 x 10(9)\/L, or platelets less than 50 x 10(9)\/L; permanently discontinue if WBC less than 1 x 10(9)\/L, neutrophils less than 0.5 x 10(9)\/L, or platelets less than 25 x 10(9)\/L, Hgb is less than 8.5 g\/dL<\/li><li><b>(hepatitis C) hematologic, pediatric:<\/b> reduce dose to 40 mcg\/m(2)\/wk then to 20 mcg\/m(2)\/wk (if needed) if WBC is less than 1.5 x 10(9)\/L, neutrophils less than 0.75 x 10(9)\/L, or platelets less than 70 x 10(9)\/L; permanently discontinue if WBC less than 1 x 10(9)\/L, neutrophils less than 0.5 x 10(9)\/L, platelets less than 50 x 10(9)\/L, Hgb is less than 8.5 g\/dL, or creatinine greater than 2 mg\/dL<\/li><li><b>(hepatitis C) moderate renal impairment:<\/b> (CrCl 30 to 50 mL\/min) reduce dose by 25%; discontinue if renal function decreases during treatment<\/li><li><b>(hepatitis C) severe renal impairment:<\/b> (CrCl 10 to 29 mL\/min) reduce dose by 50%; discontinue if renal function decreases during treatment; permanently discontinue peginterferon<\/li><li><b>(hepatitis C) hemodialysis:<\/b> reduce dose by 50%; discontinue if renal function decreases during treatment<\/li><li><b>(hepatitis C) renal impairment (CrCl less than 50 mL\/min):<\/b> ribavirin and peginterferon alfa-2b\/ribavirin combination should not be used<\/li><li><b>(melanoma) renal impairment (moderate, CrCl 30 to 50 mL\/min\/1.73m(2)):<\/b> initial, 4.5 mcg\/kg\/wk SUBQ for 8 doses, then 2.25 mcg\/kg\/wk SUBQ for up to 5 years<\/li><li><b>(melanoma) renal impairment (severe, CrCl less than 30 mL\/min\/1.73m(2) or ESRD on dialysis):<\/b> 3 mcg\/kg\/wk SUBQ for 8 doses, then 1.5 mcg\/kg\/wk SUBQ for up to 5 years<\/li><li><b>(melanoma) hepatic impairment:<\/b> in patients who develop hepatic decompensation (Child-Pugh scores of greater than 6), discontinue; in patients with viral hepatitis who have moderate or severe hepatic impairment (child-Pugh scores greater than 6), peginterferon alfa-2b is contraindicated<\/li><li><b>(melanoma) ECOG PS:<\/b> withhold peginterferon alfa-2b dose for Eastern College Oncology Group Performance Status (ECOG PS) of 2 or more; when the ECOG PS has improved to 0 or 1, peginterferon alfa-2b may be restarted at a modified dose - FOR DOSES 1 to 8: first dose modification, 3 mcg\/kg\/wk; second dose modification, 2 mcg\/kg\/wk; third dose modification, 1 mcg\/kg\/wk; and permanently discontinue if unable to tolerate 1 mcg\/kg\/wk; FOR DOSES 9 to 260: first dose modification, 2 mcg\/kg\/wk; second dose modification, 1 mcg\/kg\/wk; and permanently discontinue if unable to tolerate 1 mcg\/kg\/wk<\/li><li><b>(melanoma) hematological toxicity:<\/b> withhold peginterferon alfa-2b dose for any of the following hematologic toxicities: ANC of less than 0.5 x 10(9)\/L or platelet count of less than 50 x 10(9)\/L; when the ANC has increased to 0.5 x 10(9)\/L or greater or the platelet count has increased to 50 x 10(9)\/L or greater, peginterferon alfa-2b may be restarted at a modified dose - FOR DOSES 1 to 8: first dose modification, 3 mcg\/kg\/wk; second dose modification, 2 mcg\/kg\/wk; third dose modification, 1 mcg\/kg\/wk; and permanently discontinue if unable to tolerate 1 mcg\/kg\/wk; FOR DOSES 9 to 260: first dose modification, 2 mcg\/kg\/wk; second dose modification, 1 mcg\/kg\/wk; and permanently discontinue if unable to tolerate 1 mcg\/kg\/wk<\/li><li><b>(melanoma) neuropsychiatric:<\/b> permanently discontinue peginterferon alfa-2b if the patient develops persistent or worsening severe neuropsychiatric disorders<\/li><li><b>(melanoma) non-hematologic toxicity:<\/b> permanently discontinue peginterferon alfa-2b if grade 4 non-hematologic toxicity develops, or the patient is unable to tolerate a dose of 1 mcg\/kg\/wk; withhold peginterferon alfa-2b dose if grade 3 non-hematologic toxicity develops; when the non-hematologic toxicity has completely resolved or improved to grade 1 from grade 3 then modify the dose as follows - FOR DOSES 1 to 8: first dose modification, 3 mcg\/kg\/wk; second dose modification, 2 mcg\/kg\/wk; third dose modification, 1 mcg\/kg\/wk; and permanently discontinue if unable to tolerate 1 mcg\/kg\/wk; FOR DOSES 9 to 260: first dose modification, 2 mcg\/kg\/wk; second dose modification, 1 mcg\/kg\/wk; and permanently discontinue if unable to tolerate 1 mcg\/kg\/wk<\/li><li><b>(melanoma) retinopathy:<\/b> permanently discontinue peginterferon alfa-2b if new or worsening retinopathy develops<\/li><\/ul>"},{"id":"926101-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hepatitis C, chronic, Combination therapy following prior treatment failure in compensated liver disease<\/li><li>Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease<\/li><li>Hepatitis C, chronic, Monotherapy in interferon alpha-naive with compensated liver disease<\/li><li>Malignant melanoma; Adjunct<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Condyloma acuminatum, Treatment-resistant - HIV infection<\/li><li>Essential thrombocythemia<\/li><li>Hepatitis C, chronic, In patients with compensated liver disease - HIV infection<\/li><\/ul>"}]},{"id":"926101-s-2","title":"Black Box Warning","mono":"<ul><li><b>Subcutaneous (Powder for Solution)<\/b><br\/>PegIntron(R) may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of these conditions. Use with ribavirin: Ribavirin may cause birth defects and fetal death, and extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia, which may result in a worsening of cardiac disease.<br\/><\/li><li><b>Subcutaneous (Powder for Solution)<\/b><br\/>Sylatron(TM): The risk of serious depression, with suicidal ideation and completed suicides, and other serious neuropsychiatric disorders are increased with alpha interferons, including peginterferon alfa-2b. Permanently discontinue peginterferon alfa-2b in patients with persistently severe or worsening signs or symptoms of depression, psychosis, or encephalopathy. These disorders may not resolve after stopping peginterferon alfa-2b.<br\/><\/li><\/ul>"},{"id":"926101-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926101-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylaxis, history to peginterferon alfa-2b or interferon alfa-2b<\/li><li>hemoglobinopathies (eg, thalassemia major and sickle-cell anemia) (in combination with ribavirin)<\/li><li>hepatic decompensation (Child-Pugh score greater than 6 (class B or C))<\/li><li>hepatic decompensation (Child-Pugh score greater than 6; class B or C) in patients with cirrhotic chronic hepatitis C before or during therapy<\/li><li>hepatitis, autoimmune<\/li><li>hypersensitivity reaction (urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) to interferon alfa or to any component of the product<\/li><li>pregnancy or pregnant partner of male patient; may cause birth defects and death of the exposed fetus (in combination with ribavirin)<\/li><li>renal function impairment (CrCl less than 50 mL\/min) (in combination with ribavirin)<\/li><\/ul>"},{"id":"926101-s-3-10","title":"Precautions","mono":"<ul><li>anemia, hemolytic may occur; may result in worsening of cardiac disease; monitoring recommended; discontinue use if condition worsens or persists (in combination with ribavirin)<\/li><li>autoimmune disorders (eg, thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis); including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; if symptoms are persistently severe or worsen, discontinue use<\/li><li>ischemic or infectious disorders, including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; if symptoms are persistently severe or worsen, discontinue use<\/li><li>neuropsychiatric events (eg, suicide, suicidal and homicidal ideation, depression, relapse of addiction\/overdose, aggressive behavior, psychoses, hallucinations, bipolar disorders, mania, encephalopathy) including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; if symptoms are persistently severe or worsen, permanently discontinue use<\/li><li>pregnancy; avoid during therapy; use at least 2 forms of contraception and perform monthly tests; do not start ribavirin without a negative pregnancy test (in combination with ribavirin)<\/li><li>bone marrow toxicity resulting in severe cytopenias has occurred; monitoring recommended; discontinuation may be necessary<\/li><li>cardiovascular disease, including history of myocardial infarction or arrhythmic disorder; increased risk for cardiovascular adverse events; monitoring recommended; if history of significant or unstable cardiac disease, do not treat with combination peginterferon\/ribavirin<\/li><li>cardiovascular events (eg, hypotension, arrhythmia, tachycardia, cardiomyopathy, angina pectoris, and myocardial infarction) have occurred; permanently discontinue for new-onset ventricular arrhythmia or cardiovascular decompensation<\/li><li>cerebrovascular events, ischemic and hemorrhagic, have been reported<\/li><li>cirrhosis; increased risk of hepatic decompensation and death; monitoring recommended; permanently discontinue for severe (Grade 3) hepatic injury or hepatic decompensation (Child-Pugh score greater than 6 (class B or C))<\/li><li>cirrhotic chronic hepatitis C; increased risk of hepatic decompensation and death; monitoring recommended; discontinue treatment if Child-Pugh scores greater than 6<\/li><li>cirrhotic chronic hepatitis C patients co-infected with HIV receiving HAART (efficacy not established); increased risk of hepatic decompensation; monitoring recommended; discontinue if Child-Pugh scores greater than 6<\/li><li>colitis, ulcerative or hemorrhagic\/ischemic, has been reported, usually within 12 weeks of therapy initiation, with some cases fatal; discontinue if signs and symptoms develop<\/li><li>cutaneous eruptions, serious (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), have been reported; discontinue treatment if a reaction develops<\/li><li>debilitating medical condition (eg, history of pulmonary disease, COPD); increased risk of fever and flu-like symptoms<\/li><li>dental and periodontal disorders have been reported; monitoring recommended (in combination with ribavirin)<\/li><li>higher doses; encephalopathy has been reported, especially in the elderly<\/li><li>hyperglycemia, diabetes mellitus, and type 1 diabetes have been reported; may cause or exacerbate; if uncontrolled disease preexists, do not initiate therapy; if uncontrolled disease develops during therapy, permanently discontinue treatment<\/li><li>hypersensitivity reactions, serious and acute, have been reported; discontinue treatment if serious acute reaction develops (transient rash does not necessitate interruption of treatment)<\/li><li>hyperthyroidism or hypothyroidism has been reported; may cause or exacerbate; if uncontrolled disease preexists, do not initiate therapy; if uncontrolled disease develops during therapy, permanently discontinue treatment<\/li><li>hypertriglyceridemia may occur; monitoring recommended; may increase risk of pancreatitis<\/li><li>long-term use; increased risk of dry mouth and dental and periodontal disorders; monitoring recommended (in combination with ribavirin)<\/li><li>ophthalmologic disorders, (eg, vision loss, retinopathy, optic neuritis, papilledema, serous retinal detachment, macular edema, retinal artery or vein thrombosis) may be induced or aggravated; monitoring recommended; permanently discontinue therapy if new or worsening disorders develop<\/li><li>organ transplant recipients; incidence of renal failure higher in patients receiving combination peginterferon\/ribavirin treatment<\/li><li>pancreatitis has been reported, with some cases fatal; suspend treatment if signs\/symptoms suggestive of pancreatitis occur; discontinue treatment if confirmed<\/li><li>pediatric patients; height and weight gain have been inhibited, including some cases of severely inhibited growth velocity (in combination with ribavirin)<\/li><li>psychiatric and\/or substance use disorders, history or current; risk of new onset or worsening of condition; monitoring recommended; drug discontinuation may be warranted<\/li><li>pulmonary function impairment (eg, dyspnea, pulmonary infiltrates, interstitial pneumonitis, bronchiolitis obliterans, pneumonia, and sarcoidosis), including fatal or life-threatening events, may be induced or aggravated; suspend treatment if pulmonary function impairment develops; closely monitor if treatment is reinitiated<\/li><li>renal function decline during treatment; discontinue therapy<\/li><li>renal function impairment (CrCl less than 50 mL\/min); monitoring recommended with peginterferon alfa-2b monotherapy; may require dose reduction or discontinuation; combination therapy with ribavirin is contraindicated<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"926101-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"926101-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"926101-s-4","title":"Drug Interactions","sub":[{"id":"926101-s-4-13","title":"Contraindicated","mono":"<ul>Thioridazine (theoretical)<\/ul>"},{"id":"926101-s-4-14","title":"Major","mono":"<ul><li>Aminophylline (theoretical)<\/li><li>Amitriptyline (probable)<\/li><li>Anagrelide (theoretical)<\/li><li>Clomipramine (probable)<\/li><li>Clozapine (theoretical)<\/li><li>Desipramine (probable)<\/li><li>Donepezil (theoretical)<\/li><li>Doxepin (probable)<\/li><li>Doxorubicin (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Imipramine (probable)<\/li><li>Nortriptyline (probable)<\/li><li>Perphenazine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Rasagiline (theoretical)<\/li><li>Ropivacaine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trimipramine (probable)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}]},{"id":"926101-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (melanoma, 34%; hepatitis C virus (monotherapy), 22%; hepatitis C virus (combination therapy), 36%; hepatitis C virus (monotherapy, pediatric) 17%), Erythema at injection site (hepatitis C virus (monotherapy, pediatric) 29%), Injection site reaction (melanoma, 62%; hepatitis C virus (monotherapy), 47%; hepatitis C virus (combination therapy), 75%)<\/li><li><b>Gastrointestinal:<\/b>Decrease in appetite (hepatitis C virus (monotherapy, pediatric), 22%), Loss of appetite (melanoma, 69%; hepatitis C virus (monotherapy), 20%; hepatitis C virus (combination therapy), 32%; hepatitis C virus (monotherapy, pediatric) 29%), Nausea (melanoma, 64%; hepatitis C virus (monotherapy), 26%; hepatitis C virus (combination therapy), 43%; hepatitis C virus (monotherapy, pediatric) 18%), Vomiting (melanoma, 26%; hepatitis C virus (monotherapy), 7%; hepatitis C virus (combination therapy), 14%; hepatitis C virus (monotherapy, pediatric) 27%)<\/li><li><b>Hepatic:<\/b>Increased liver enzymes (melanoma, 77%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (melanoma, 51%; hepatitis C virus (monotherapy), 23%; hepatitis C virus (combination therapy), 34%; hepatitis C virus (monotherapy, pediatric) 17%), Myalgia (melanoma, 68%; hepatitis C virus (monotherapy), 54%; hepatitis C virus (combination therapy), 56%; hepatitis C virus (monotherapy, pediatric) 17%)<\/li><li><b>Neurologic:<\/b>Dizziness (melanoma, 35%; hepatitis C virus (monotherapy), 12%; hepatitis C virus (combination therapy), 21%; hepatitis C virus (monotherapy, pediatric) 14%), Headache (melanoma, 70%; hepatitis C virus (monotherapy), 56%; hepatitis C virus (combination therapy), 62%; hepatitis C virus (monotherapy, pediatric) 62%)<\/li><li><b>Other:<\/b>Fatigue (melanoma, 94%; hepatitis C virus (monotherapy), 52%; hepatitis C virus (combination therapy), 66%; hepatitis C virus (monotherapy, pediatric) 30%), Fever (melanoma, 75%; hepatitis C virus (monotherapy), 22%; hepatitis C virus (combination therapy), 46%; hepatitis C virus (monotherapy, pediatric) 80%), Rigor (melanoma, 63%; hepatitis C virus (monotherapy), 23%; hepatitis C virus (combination therapy), 48%; hepatitis C virus (monotherapy, pediatric) 21%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bundle branch block, Cardiomyopathy, Hypotension, Myocardial infarction, Supraventricular arrhythmia, Ventricular tachycardia<\/li><li><b>Gastrointestinal:<\/b>Colitis, Pancreatitis (hepatitis C virus (combination therapy), less than 1%)<\/li><li><b>Hematologic:<\/b>Anemia (hepatitis C virus (combination therapy), 12%; hepatitis C virus (monotherapy, pediatric) 11%), Thrombocytopenia (hepatitis C virus (monotherapy), 7%; hepatitis C virus (combination therapy), 5%)<\/li><li><b>Neurologic:<\/b>Encephalopathy<\/li><li><b>Ophthalmic:<\/b>Blindness AND\/OR vision impairment level (melanoma, less than 1%; hepatitis C virus (combination therapy), less than 1%), Optic neuritis (hepatitis C virus (combination therapy), less than 1%), Retinal hemorrhage, Thrombosis of retinal vein (hepatitis C virus (combination therapy), less than 1%)<\/li><li><b>Psychiatric:<\/b>Aggressive behavior, Bipolar disorder, Depression (Melanoma, 59%; hepatitis C virus (monotherapy), 29%; hepatitis C virus (combination therapy), 31%), Hallucinations, Homicidal thoughts, Suicidal thoughts, Suicide<\/li><\/ul>"},{"id":"926101-s-6","title":"Drug Name Info","sub":{"0":{"id":"926101-s-6-17","title":"US Trade Names","mono":"<ul><li>PEG-Intron<\/li><li>Peg Intron RP<\/li><li>Sylatron<\/li><\/ul>"},"2":{"id":"926101-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Interferon, Alfa (class)<\/li><\/ul>"},"3":{"id":"926101-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926101-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"926101-s-7","title":"Mechanism Of Action","mono":"Alpha-interferons induce various cellular activities related to binding with specific cell-surface membrane receptors; these include suppression of cell proliferation, antiviral activity, and  immunomodulating effects, such as augmentation of macrophage phagocytic  activity. The exact mechanism of action of peginterferon alfa-2b in patients with melanoma is unknown. In chronic hepatitis C, peginterferon alfa-2b induces the innate antiviral immune response. The antiviral activity of peginterferon alfa-2b is enhanced by combined use of oral ribavirin in chronic hepatitis C patients.<br\/>"},{"id":"926101-s-8","title":"Pharmacokinetics","sub":[{"id":"926101-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, subQ: increases with multiple-dosing<\/li><li>Tmax, subQ: 15 to 44 hours.<\/li><\/ul>"},{"id":"926101-s-8-24","title":"Distribution","mono":"Vd: 1.4 L\/kg <br\/>"},{"id":"926101-s-8-25","title":"Metabolism","mono":"Liver: extent unknown.<br\/>"},{"id":"926101-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 30%<\/li><li>Total body clearance: 22 mL\/hr x kg<\/li><li>Total body clearance: 17% reduction (moderate renal impairment); 44% reduction (severe renal impairment)<\/li><li>Dialyzable, hemodialysis: not significantly removed<\/li><\/ul>"},{"id":"926101-s-8-27","title":"Elimination Half Life","mono":"40 hours (range 22 to 60 hours) <br\/>"}]},{"id":"926101-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>(Redipen(R)) Manufacturing in the United States is being voluntarily discontinued with anticipated exhaustion of inventory around July, 2015; this is not related to any safety or efficacy concerns.<\/li><li>(Redipen(R)) To reconstitute the drug, hold the pen upright and press the 2 halves together until they click; gently invert pen to mix (do not shake) and use immediately.<\/li><li>(Redipen(R)) Keep the pen upright and attach the supplied needle; to select appropriate dose, pull back on the dosing button until the dark bands are visible and turn the button until the dark band is aligned with the correct dose.<\/li><li>(Redipen(R)) The pen is for single use only and, after reconstitution, cannot be stored for more than 24 hours at 2 to 8 degrees C; discard unused portion.<\/li><li>(Pegintron(R) vials; Sylatron(TM)) Reconstitute with 0.7 mL of supplied diluent only and swirl gently; do not shake.<\/li><li>(Pegintron(R) vials) Do not add other medications or diluents to the solution.<\/li><li>(Pegintron(R) vials; Sylatron(TM)) The vial is for single use only and, after reconstitution, cannot be stored for more than 24 hours at 2 to 8 degrees C (36 to 46 degrees F); discard unused diluent and solution.<\/li><li>(Sylatron(TM)) Rotate injection sites.<\/li><li>When coadministered with ribavirin, take ribavirin with food.<\/li><\/ul>"},{"id":"926101-s-10","title":"Monitoring","mono":"<ul><li>(chronic hepatitis C) HCV-RNA titers periodically during therapy; reduction from baseline of at least 2 log(10) by week 12, or undetectable HCV-RNA after 24 weeks of therapy, and maintaining a sustained virological response for 24 weeks after receiving last dose is indicative of efficacy;  monitor hepatic function for evidence of improvement<\/li><li>(melanoma) objective evidence of tumor response is indicative of efficacy<\/li><li>neuropsychiatric events, including development or worsening of depression, suicidality, and other unusual changes in behavior; every 3 weeks during the initial 8 weeks of treatment, every 6 months thereafter while on therapy, and for at least 6 months after discontinuing treatment<\/li><li>blood chemistries; at baseline, and periodically thereafter<\/li><li>CBC, including differential; at baseline, at 2 weeks and 4 weeks of treatment, and periodically thereafter<\/li><li>hepatic function, including serum bilirubin, ALT, AST, alkaline phosphatase, and LDH; at 2 and 8 weeks and 2 and 3 months following therapy initiation, and every 6 months thereafter during therapy<\/li><li>pregnancy test, in patients receiving concomitant ribavirin; immediately prior, monthly during therapy and for 6 months after discontinuation of treatment<\/li><li>renal function; serum creatinine in patients with impaired renal function<\/li><li>TSH; within 4 weeks of treatment initiation, at 3 and 6 months following initiation, and every 6 months thereafter during therapy<\/li><li>triglycerides; periodically during therapy<\/li><li>ECG; prior to initiation of therapy in patients with preexisting cardiac abnormalities receiving concomitant ribavirin<\/li><li>ophthalmologic examination; baseline  (including indirect ophthalmoscopy or fundus photography in patients with preexisting retinopathy), periodically during therapy for patients with preexisting ophthalmologic disorders, and promptly in any patient exhibiting ocular symptoms<\/li><li>signs and symptoms of pulmonary disorders, in patients with a history of pulmonary infiltrates or impaired pulmonary function during previous alpha interferon administration<\/li><\/ul>"},{"id":"926101-s-11","title":"How Supplied","mono":"<ul><li><b>PEGIntron<\/b><br\/><ul><li>  Kit: 50 MCG, 80 MCG, 120 MCG, 150 MCG<\/li><li>Subcutaneous Powder for Solution: 50 MCG, 80 MCG, 120 MCG, 150 MCG<\/li><\/ul><\/li><li><b>Peg Intron RP<\/b><br\/>  Kit: 150 MCG<br\/><\/li><li><b>Sylatron<\/b><br\/>Subcutaneous Powder for Solution: 200 MCG, 300 MCG, 600 MCG<br\/><\/li><\/ul>"},{"id":"926101-s-12","title":"Toxicology","sub":[{"id":"926101-s-12-31","title":"Clinical Effects","mono":"<b>INTERFERONS<\/b><br\/>OVERDOSE: Data are limited. Shivers, myalgias, low grade fever and tachycardia have been reported. ADVERSE EFFECTS: \"flu-like\" symptoms (fever, chills, tachycardia, headache, malaise, and myalgias), hypotension, seizures, headache, lethargy, fatigue, elevated liver enzymes, leukopenia, & renal insufficiency; dysrhythmias in patients with underlying heart disease. Vomiting, diarrhea, hyperkalemia, hypocalcemia occur at high doses.<br\/>"},{"id":"926101-s-12-32","title":"Treatment","mono":"<b>INTERFERONS<\/b><br\/><ul><li>Decontamination: Not indicated; broken down in the gut on oral ingestion.<\/li><li>Influenza-like illness: Treat with acetaminophen or non-steroidal anti-inflammatory agents<\/li><li>Hypotensive episode: Transient, usually requires no treatment;  0.9% NaCl 10-20 ml\/kg, dopamine, epinephrine if persistent<\/li><li>Monitoring of patient: CBC, hepatic &amp; renal function; ECG, calcium, potassium if severe overdose.<\/li><\/ul>"},{"id":"926101-s-12-33","title":"Range of Toxicity","mono":"<b>INTERFERONS<\/b><br\/>Single doses greater than 100-200 million units associated with toxicity. <br\/>"}]},{"id":"926101-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise hepatitis patient also using ribavirin to avoid pregnancy by using 2 forms of birth control during therapy and for 6 months after last dose. A female partner of a male patient should also avoid pregnancy, as ribavirin may cause birth defects and fetal death.<\/li><li>Drug may cause fatigue, pyrexia, headaches, anorexia, myalgia, nausea, chills, and injection-site reactions.<\/li><li>Instruct patient to immediately report signs\/symptoms of depression, suicidal ideation, aggression, behavioral changes, or any psychiatric symptoms during treatment and up to 6 months after the last dose.<\/li><li>Counsel patient to immediately report signs\/symptoms of hypotension, arrhythmia, tachycardia, cardiomyopathy, angina pectoris, or myocardial infarction.<\/li><li>Advise patient to immediately report vision changes or signs\/symptoms of new or worsening retinopathy.<\/li><li>If self-administered, instruct patient about proper technique and placement of injections, including rotation of injection sites.<\/li><\/ul>"}]}